# PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

> **NCT02544880** · PHASE1 · COMPLETED · sponsor: **Donald T. Weed, MD, FACS** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **DRUG:** Tadalafil
- **BIOLOGICAL:** Anti-MUC1 Vaccine
- **BIOLOGICAL:** Anti-Influenza Vaccine
- **OTHER:** Tadalafil Placebo
- **OTHER:** Anti-MUC1 Vaccine Placebo
- **OTHER:** Standard of Care Treatment
- **OTHER:** Anti-Influenza Vaccine Placebo

## Key facts

- **NCT ID:** NCT02544880
- **Lead sponsor:** Donald T. Weed, MD, FACS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-25
- **Primary completion:** 2019-06-02
- **Final completion:** 2021-06-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544880, "PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02544880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*